ERBB2 and breast carcinoma: Imlunestrant (LY3484356) is a novel orally bioavailable SERD with pure antagonistic properties that showed a favorable profile as monotherapy in the study EMBER (NCT04188548) in ER+, HER2− advanced breast cancer [89].